We have looked at 52 single samples from newly diagnosed HER2-positive breast cancer tumors in the RESPONSIFY project [20] using Affymetrix SNP 6.0 arrays, WES and pathologist purity estimates. This evidence concerns the gene ERBB2 and breast cancer.